Brokers Issue Forecasts for Gilead Sciences Q2 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Zacks Research lifted their Q2 2025 EPS estimates for Gilead Sciences in a research report issued to clients and investors on Thursday, May 8th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.93 for the quarter, up from their prior forecast of $1.92. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.07 EPS, Q4 2025 earnings at $1.99 EPS, FY2025 earnings at $7.80 EPS, Q1 2026 earnings at $1.68 EPS, Q3 2026 earnings at $2.21 EPS and Q4 2026 earnings at $2.31 EPS.

Several other research analysts also recently commented on GILD. Oppenheimer decreased their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a research note on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Trading Down 2.3%

GILD stock opened at $101.43 on Monday. The company has a market capitalization of $126.30 billion, a PE ratio of 274.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. Gilead Sciences has a one year low of $62.07 and a one year high of $119.96. The company’s 50 day moving average price is $106.71 and its two-hundred day moving average price is $99.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s quarterly revenue was down .3% on a year-over-year basis. During the same period last year, the firm posted ($1.32) earnings per share.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.12%. Gilead Sciences’s dividend payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at $19,977,938.37. The trade was a 9.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold a total of 22,929 shares of company stock valued at $2,644,895 in the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its position in Gilead Sciences by 0.5% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 324,469 shares of the biopharmaceutical company’s stock valued at $29,971,000 after acquiring an additional 1,458 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in Gilead Sciences by 2.3% in the 4th quarter. Harbor Capital Advisors Inc. now owns 27,621 shares of the biopharmaceutical company’s stock valued at $2,551,000 after acquiring an additional 616 shares in the last quarter. Czech National Bank lifted its position in Gilead Sciences by 6.5% in the 4th quarter. Czech National Bank now owns 270,216 shares of the biopharmaceutical company’s stock valued at $24,960,000 after acquiring an additional 16,598 shares in the last quarter. Aprio Wealth Management LLC lifted its position in Gilead Sciences by 124.7% in the 4th quarter. Aprio Wealth Management LLC now owns 7,766 shares of the biopharmaceutical company’s stock valued at $717,000 after acquiring an additional 4,310 shares in the last quarter. Finally, Matrix Trust Co lifted its position in Gilead Sciences by 515.2% in the 4th quarter. Matrix Trust Co now owns 1,052 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 881 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.